As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $10.41, down -2.07% from its previous closing price of $10.63. On the day, 3317972 shares were traded. ARQT stock price reached its highest trading level at $11.09 during the session, while it also had its lowest trading level at $10.21.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.80 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 2.32 whereas as Long-Term Debt/Eq ratio is at 2.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 when Burnett Patrick sold 1,325 shares for $3.54 per share. The transaction valued at 4,692 led to the insider holds 57,032 shares of the business.
Matsuda Masaru sold 1,850 shares of ARQT for $3,661 on Nov 21. The insider now owns 46,634 shares after completing the transaction at $1.98 per share. On Oct 24, another insider, Frazier Life Sciences VIII, L., who serves as the 10% Owner of the company, bought 80,000 shares for $2.50 each. As a result, the insider paid 200,000 and bolstered with 8,764,232 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1.01B and an Enterprise Value of 941.88M. For the stock, the TTM Price-to-Sale (P/S) ratio is 273.06 while its Price-to-Book (P/B) ratio in mrq is 11.36. Its current Enterprise Value per Revenue stands at 15.80 whereas that against EBITDA is -4.13.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $17.57, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is 5.17, while the 200-Day Moving Average is calculated to be 6.30.
Shares Statistics:
It appears that ARQT traded 5.93M shares on average per day over the past three months and 5.44M shares per day over the past ten days. A total of 96.79M shares are outstanding, with a floating share count of 79.55M. Insiders hold about 17.81% of the company’s shares, while institutions hold 97.01% stake in the company. Shares short for ARQT as of Feb 15, 2024 were 16.94M with a Short Ratio of 2.86, compared to 20.83M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.50% and a Short% of Float of 21.96%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.76 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.97, while EPS last year was -$1.31. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.64 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$2.03 and -$3.46 for the fiscal current year, implying an average EPS of -$2.56. EPS for the following year is -$1.55, with 7 analysts recommending between -$0.89 and -$1.95.
Revenue Estimates
In the current quarter, 4 analysts expect revenue to total $12.27M. It ranges from a high estimate of $13.2M to a low estimate of $10.5M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $2.78M, an estimated increase of 341.20% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $16.97M, an increase of 227.00% less than the figure of $341.20% in the same quarter last year. There is a high estimate of $19.9M for the next quarter, whereas the lowest estimate is $12.8M.
A total of 7 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $110.6M, while the lowest revenue estimate was $69.6M, resulting in an average revenue estimate of $90.01M. In the same quarter a year ago, actual revenue was $59.61M, up 51.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $198.2M in the next fiscal year. The high estimate is $246.9M and the low estimate is $164.5M. The average revenue growth estimate for next year is up 120.20% from the average revenue estimate for this year.
